title: Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals.
abstract: Since several years, the use of intravenous immunoglobulins (IVIg) has increased. This growth has encouraged some countries to publish guidelines. In parallel, some countries have conducted audits to know how IVIg are used in clinical practice in the light of the available guidelines. The objective of this study was to assess IVIg use in three French university hospitals in 2006. All IVIg administrations were evaluated during 6 months (12 September 2005-12 March 2006) in French university hospitals of Marseille. Different data were recorded for each administration: patient characteristics, indication, formulation and quantity. During the study period, 2802 administrations of IVIg (corresponding to a total quantity of 76 780 g) have been recorded. Four hundred and thirty-five patients received at least one of these administrations. The five most reported indications were multifocal motor neuropathy (11.0% of total quantity), chronic inflammatory demyelinating polyradiculoneuropathy (10.2%), corticoresistant dermatomyositis (10.2%), immune thrombocytopaenia (9.9%) and primary immune deficiency (9.1%). According to available French recommendations, 70% of the IVIg use was for 'acknowledged indications', 9% for 'indications to be assessed' and 18% for 'unwarranted indications'. The 10 most reported indications were 'acknowledged indications' according to available recommendations of the French expert group. Nevertheless, the two most reported indications were not approved by the French Health Products Agency (AFSSAPS) at the time of the study and were approved since.
authors.affiliation: Assistance Publique des Hôpitaux de Marseille, France.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Frauger
authors.forename: Jerome
authors.initials: J
authors.lastname: Grassi
authors.forename: Vincent
authors.initials: V
authors.lastname: Pradel
authors.forename: Charleric
authors.initials: C
authors.lastname: Bornet
authors.forename: Frank
authors.initials: F
authors.lastname: Rouby
authors.forename: Jean
authors.initials: J
authors.lastname: Delorme
authors.forename: Sebastien
authors.initials: S
authors.lastname: Ousset
authors.forename: Diane
authors.initials: D
authors.lastname: Braguer
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Azulay
authors.forename: Christine
authors.initials: C
authors.lastname: Penot-Ragon
authors.forename: Jean-Robert
authors.initials: JR
authors.lastname: Harle
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Bongrand
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Weiller
authors.forename: Jean
authors.initials: J
authors.lastname: Pouget
authors.forename: Gérard
authors.initials: G
authors.lastname: Michel
authors.forename: Joelle
authors.initials: J
authors.lastname: Micallef
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Reynier
authors.forename: Sophie
authors.initials: S
authors.lastname: Tardieu
authors.forename: Patrice
authors.initials: P
authors.lastname: Vanelle
authors.forename: Olivier
authors.initials: O
authors.lastname: Blin
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D005602:France; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D056687:Off-Label Use; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D055815:Young Adult
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors